Bromoenterobactins as potent inhibitors of a pathogen-associated, siderophore-modifying C-glycosyltransferase.

J Am Chem Soc
Authors
Keywords
Abstract

IroB is a C-glycosyltransferase encoded in the iroA cluster. C-Glucosylation of the bacterial siderophore enterobactin by IroB is a strategy some pathogenic bacteria use to evade the host's innate immunity mediated by lipocalin 2 (Lcn2). Without this modification, enterobactin can be tightly bound by host Lcn2, rendering it ineffective as a siderophore. Therefore, IroB inhibitors could be potential antibiotics against iroA-harboring pathogenic bacteria. We used enterobactin analogues to probe the properties of the active site of IroB and found that enterobactin analogues brominated at the C5 positions of the 2,3-dihydroxybenzoyl rings are potent inhibitors of IroB. This finding could lead to the discovery of effective antibiotics targeting iroA-containing bacteria.

Year of Publication
2006
Journal
J Am Chem Soc
Volume
128
Issue
29
Pages
9324-5
Date Published
2006 Jul 26
ISSN
0002-7863
DOI
10.1021/ja063236x
PubMed ID
16848455
Links
Grant list
AI 47238 / AI / NIAID NIH HHS / United States
R01GM065400 / GM / NIGMS NIH HHS / United States